Key result
Multibiomarker strategies improve diagnostic accuracy and early risk stratification in acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
The incidence of acute myocardial infarction (AMI) has been increasing rapidly in recent years, seriously endangering human health. Cardiac biomarkers play critical roles in the diagnosis and prognosis of AMI. Troponin is a highly sensitive and specific biomarker for AMI diagnosis and can independently predict adverse cardiac events. Other biomarkers such as N-terminal B-type natriuretic peptide and C reactive protein are also valuable predictors of cardiovascular prognosis. Recently, several novel biomarkers have been identified for the diagnosis and risk assessment in patients with AMI. A multibiomarker approach can potentially enhance the diagnostic accuracy and provide more information for the early risk stratification of AMI. In this review, we will summarise the biomarkers discovered in recent years and focus on their diagnostic and prognostic value for patients with AMI.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2019) conducted a review in Acute myocardial infarction (AMI). Cardiac biomarkers (including troponin, N-terminal B-type natriuretic peptide, C-reactive protein, and novel biomarkers) was evaluated on Diagnosis and prognosis of acute myocardial infarction. Cardiac biomarkers, especially in a multibiomarker approach, enhance diagnostic accuracy and early risk stratification in acute myocardial infarction.
Synapse has enriched 5 related papers. Consider them for comparative context: